原发性胆道胆管炎的新治疗方法

IF 0.4 4区医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL

M S-medecine Sciences Pub Date : 2025-08-01 Epub Date: 2025-09-08 DOI:10.1051/medsci/2025109

Corentin Brice, Alexandre Louvet

{"title":"原发性胆道胆管炎的新治疗方法","authors":"Corentin Brice, Alexandre Louvet","doi":"10.1051/medsci/2025109","DOIUrl":null,"url":null,"abstract":"Primary biliary cholangitis (PBC) is a rare disease for which management long consisted of a single treatment: ursodeoxycholic acid. In 2015-2016, this disease regained interest with the first studies on obeticholic acid (FXR agonist) and then on bezafibrate (PPAR agonist). Subsequently, over the past five years, significant progress has been made in the management of PBC. Major studies have helped better predict disease progression and its response to treatment through the development of prognostic tools. Additionally, the therapeutic arsenal has expanded with the arrival of selective PPAR agonists.","PeriodicalId":18205,"journal":{"name":"M S-medecine Sciences","volume":"41 8-9","pages":"693-700"},"PeriodicalIF":0.4000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[New therapeutic approaches for the treatment of primary biliary cholangitis].\",\"authors\":\"Corentin Brice, Alexandre Louvet\",\"doi\":\"10.1051/medsci/2025109\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Primary biliary cholangitis (PBC) is a rare disease for which management long consisted of a single treatment: ursodeoxycholic acid. In 2015-2016, this disease regained interest with the first studies on obeticholic acid (FXR agonist) and then on bezafibrate (PPAR agonist). Subsequently, over the past five years, significant progress has been made in the management of PBC. Major studies have helped better predict disease progression and its response to treatment through the development of prognostic tools. Additionally, the therapeutic arsenal has expanded with the arrival of selective PPAR agonists.\",\"PeriodicalId\":18205,\"journal\":{\"name\":\"M S-medecine Sciences\",\"volume\":\"41 8-9\",\"pages\":\"693-700\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"M S-medecine Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1051/medsci/2025109\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"M S-medecine Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1051/medsci/2025109","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/8 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

原发性胆道胆管炎（PBC）是一种罕见的疾病，其管理长期由单一治疗组成：熊去氧胆酸。2015-2016年，随着奥比胆酸（FXR激动剂）和贝扎布特（PPAR激动剂）的研究，该疾病重新引起人们的兴趣。随后，在过去的五年中，中国人民银行的管理取得了重大进展。主要研究通过发展预后工具帮助更好地预测疾病进展及其对治疗的反应。此外，随着选择性PPAR激动剂的出现，治疗武器库也扩大了。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[New therapeutic approaches for the treatment of primary biliary cholangitis].

Primary biliary cholangitis (PBC) is a rare disease for which management long consisted of a single treatment: ursodeoxycholic acid. In 2015-2016, this disease regained interest with the first studies on obeticholic acid (FXR agonist) and then on bezafibrate (PPAR agonist). Subsequently, over the past five years, significant progress has been made in the management of PBC. Major studies have helped better predict disease progression and its response to treatment through the development of prognostic tools. Additionally, the therapeutic arsenal has expanded with the arrival of selective PPAR agonists.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

M S-medecine Sciences 医学-医学：研究与实验

CiteScore

0.80

自引率

14.30%

发文量

182

审稿时长

4-8 weeks

期刊介绍： m/s offers high-quality review articles in French, covering all areas of biomedical and health research, in a monthly magazine format (10 issues / year). m/s is read by the whole French-speaking community, in France but also in Belgium, Switzerland, Canada, Morocco, Algeria, Tunisia etc. m/s is not a primary publication, and thus will not consider unpublished data. Most articles are invited by the Editors, but spontaneous proposals are welcomed. Each issue combines news and views on the most recent scientific publications, as well as broadly accessible and updated review articles on a specific topic, and essays on science and society, history of science, public health, or reactions to published articles. Each year, m/s also publishes one or two thematic issues focused on a research topic of high interest. All review articles and essays are peer-reviewed.